Novartis PH lb HDM201, MBG453 and venetoclax in AML or high risk MDS - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn more about how the study drug combinations (HDM201+MBG452 and HDM201+venetoclax) effect people with AML and MDS.
R/R Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Who Can Participate in the Study?
Adults who have:
-Relapsed/Refactory AML after having more than 1 prior therapy but less than 3 who have relapsed
-No acute promyelocytic leukemia with PML-RARA.
-No stem cell transplant within last 6 months and/or active GvHD requiring systemic immunosuppressive therapy.
-No active, known or suspected autoimmune disease
What is Involved?
If you choose to join this study you will:
- Complete your standard of care (including blood tests, physical exams, etc.)
- Be given a small dose of the study drug (HDM201+MBG452 and HDM201+venetoclax)
- Be given increased amounts of the study drug until the known recommended dose is found
- Have a bone marrow aspirate or biopsy (small sample of tissue removed) at the time of joining
Study Details
